Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115841) titled 'A Study on the Safety, Efficacy, and Prognostic Value of SGLT2 Inhibitors in Hypertrophic Cardiomyopathy' on Dec. 31, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Shanghai General Hospital
Condition:
hypertrophic cardiomyopathy (HCM)
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2025-12-31
Target Sample Size: No-SGLT2i group vs SGLT2 inhibitor treatment group:1300;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=303409
Published by HT Digital Content Services with permission from Health Dail...